A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma.

A Phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by Paclitaxel/Carboplatin chemotherapy in patients with high risk, early stage endometrial Carcinoma

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T-Cell Lymphoma (TCL)

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Randomized Phase 3 study of Eryaspase in combination with either Gemcitibine/ Abraxane or FOLFIRI compared with Gemcitibine/ Abraxane or FOLFIRI alone as second line therapy in patients with stage III/IV pancreatic cancer

A Phase 1/2, open-label, multi-arm study, of AGEN1884 in combination with AGEN2034 in subjects with cervical cancer